Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
Mergers & Acquisitions

Halozyme and Vertex Sign Global Licensing Deal for Hypercon Drug Delivery Technology

Halozyme’s subsidiary signed an exclusive global agreement with Vertex to apply Hypercon™ drug delivery technology to up to three targets, with upfront payment, milestones, and royalties tied to…

Written bySamiksha JadhavReviewed byPharmacally Editorial Team8 April 2026 · 2 min read
Fact-Checked
Leiden_Ext_Entrance_Vertex_2021_11zon

Halozyme and Vertex enter global licensing deal for Hypercon™ technology across up to three targets, including $15M upfront, milestones, and royalties for concentrated biologic delivery.

Halozyme Therapeutics, Inc. announced that its wholly owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated to apply Halozyme’s Hypercon™ drug delivery technology across up to three drug targets.

Hypercon Technology Aims to Reduce Injection Volume

Hypercon™ is a microparticle-based technology designed to enable hyperconcentration of drugs and biologics. By increasing concentration, the platform reduces injection volume while maintaining the same dose. This approach may support patient-friendly administration, including potential at-home delivery of biologics.

Executive Commentary Highlights Strategic Fit

Helen Torley, President and Chief Executive Officer of Halozyme, said the agreement highlights the versatility of the Hypercon platform for enabling small-volume, patient-delivered biologics. She noted that Vertex’s expertise in developing therapies for serious diseases could help expand access to targeted biologics using the technology.

Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex, stated that adding Hypercon to the company’s drug delivery capabilities could support development of transformative therapies. He added that Vertex plans to explore the technology across selected programs.

Financial Terms and Scope

Under the agreement, Vertex receives an exclusive license to use Hypercon technology for up to three targets. Halozyme will receive a $15 million upfront payment and is eligible for additional development and commercial milestone payments. The company will also earn royalties on net sales of any products developed using the Hypercon platform.

The collaboration expands Halozyme’s drug delivery partnerships while providing Vertex with a technology designed to enable concentrated biologic formulations and potentially more convenient administration.

Reference

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology, 07 April 2026, https://ir.halozyme.com/news/news-details/2026/Halozyme-Announces-Global-Collaboration-and-License-Agreement-with-Vertex-Pharmaceuticals-for-Hypercon-Technology/default.aspx

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →